474 related articles for article (PubMed ID: 15185309)
1. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
[TBL] [Abstract][Full Text] [Related]
2. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
3. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
4. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.
Pereira TN; Lewindon PJ; Smith JL; Murphy TL; Lincoln DJ; Shepherd RW; Ramm GA
J Hepatol; 2004 Oct; 41(4):576-83. PubMed ID: 15464237
[TBL] [Abstract][Full Text] [Related]
5. Bile acid levels are increased in the liver of patients with steatohepatitis.
Aranha MM; Cortez-Pinto H; Costa A; da Silva IB; Camilo ME; de Moura MC; Rodrigues CM
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):519-25. PubMed ID: 18467911
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs as noninvasive diagnostic biomarkers of liver disease in children with cystic fibrosis.
Cook NL; Pereira TN; Lewindon PJ; Shepherd RW; Ramm GA
J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):247-54. PubMed ID: 25625579
[TBL] [Abstract][Full Text] [Related]
9. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
10. [Aspects of bile acid metabolism in liver diseases(author's transl)].
Horak W
Acta Med Austriaca Suppl; 1975; 4():1-38. PubMed ID: 1064281
[TBL] [Abstract][Full Text] [Related]
11. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
12. Liver disease in cystic fibrosis.
Colombo C; Apostolo MG; Assaisso M; Roman B; Bottani P
Neth J Med; 1992 Oct; 41(3-4):119-22. PubMed ID: 1470280
[TBL] [Abstract][Full Text] [Related]
13. Is significant cystic fibrosis-related liver disease a risk factor in the development of bone mineralization abnormalities?
Alex G; Catto-Smith AG; Ditchfield M; Roseby R; Robinson PJ; Cameron FJ; Oliver MR
Pediatr Pulmonol; 2006 Apr; 41(4):338-44. PubMed ID: 16477657
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease.
Pereira TN; Lewindon PJ; Greer RM; Hoskins AC; Williamson RM; Shepherd RW; Ramm GA
J Pediatr Gastroenterol Nutr; 2012 Mar; 54(3):328-35. PubMed ID: 22157922
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis.
Calvopina DA; Chatfield MD; Weis A; Coleman MA; Fernandez-Rojo MA; Noble C; Ramm LE; Leung DH; Lewindon PJ; Ramm GA
Hepatology; 2018 Dec; 68(6):2301-2316. PubMed ID: 30014495
[TBL] [Abstract][Full Text] [Related]
16. Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis.
Mendoza ME; Monte MJ; El-Mir MY; Badia MD; Marin JJ
Clin Sci (Lond); 2002 Feb; 102(2):143-50. PubMed ID: 11834134
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
Bodewes FA; Wouthuyzen-Bakker M; Bijvelds MJ; Havinga R; de Jonge HR; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G1035-42. PubMed ID: 22301109
[TBL] [Abstract][Full Text] [Related]
18. Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats.
Azer SA; Murray M; Farrell GC; Stacey NH
Hepatology; 1993 Nov; 18(5):1224-31. PubMed ID: 8225229
[TBL] [Abstract][Full Text] [Related]
19. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
